Magmetis Ventures is the first institutional fund exclusively dedicated to supporting the emerging market for psychedelic-assisted-therapy through public equity investments and strategic advisory. This new modality of therapy is based on ethnobotanical and psychoactive molecules with a long history of indigenous use. These medicines, most of which are scheduled controlled substances, are now being evaluated in FDA clinical studies to address neuropsychiatric (mental health), and neurodegenerative conditions. It is our belief that investments in this category will help alleviate mental and physical suffering on a global scale, and address the negative socioeconomic legacy of the War on Drugs,